

Table S1 Supplementary. Neuroendocrine immunohistochemical markers.

IMMUNOHISTOCHEMICAL MARKERS			N (%)
Performed in all patients			
Synaptophysin (+)			8 (100%)
Chromogranin (+)			8 (100%)
Not performed in all patients			
Other analysed markers	6 (75%)	Patients with no additional markers	2 (25%)
PSA (-)	3 (50%)		
PSA (-) & Somatostatin (+)	1 (16.67%)		
CD56 (+), CKAE3 (+)	1 (16.67%)		
NKX3 (-) in NEC	1 (16.67%)		




Figure S1 Supplementary. Overall survival Curves after confirmation of Neuroendocrine differentiation




Figure S2 Supplementary. Time elapsed since diagnostic of prostate adenocarcinoma to Neuroendocrine differentiation